NCT03323684

Brief Summary

In laparoscopic cholecystectomy, overall pain is a conglomerate of three different and clinically separate components: incisional pain (somatic pain) due to trocar insertion sites, visceral pain (deep intra abdominal pain), and shoulder pain due to peritoneal stretching and diaphragmatic irritation associated with carbon dioxide insufflation. Moreover, it has been hypothesized that intense acute pain after laparoscopic cholecystectomy may predict development of chronic pain (e.g., postlaparoscopic cholecystectomy syndrome). Without effective treatment, this ongoing pain may delay recovery, mandate inpatient admission, and thereby increase the cost of such care. Recently, the uses of peripheral axial blocks that deliver local anesthetic into the transversus abdominis fascial plane have become popular for operations that involve incision(s) of the abdominal wall. Thus, the Transversus Abdominis plane (TAP) block has been shown to reduce perioperative opioid use in elective abdominal surgery, including open appendicectomy, laparotomy, and laparoscopic cholecystectomy. However, the efficacy of the TAP block is reportedly only reliable in providing analgesia below the umbilicus. The ultrasound-guided subcostal transversus abdominis (STA) block is a recently described variation on the TAP block which produces reliable supraumbilical analgesia. Deposition of local anesthetic in this plane has shown to block dermatomes T6 to T10 with an occasional spread to T12. This variant will be discussed in our study. Currently, the Quadratus Lumborum block (QL block) is performed as one of the perioperative pain management procedures for all generations (pediatrics, pregnant, and adult) undergoing abdominal surgery. The local anesthetic injected via the approach of the posterior QL block ( QL 2 block ) can more easily extend beyond the TAP to the thoracic paravertebral space or the thoracolumbar plane, the posterior QL block entails a broader sensory-level analgesic and may generate analgesia from T7 to L1. Use of posterior QL block in laparoscopic cholecystectomy has not been investigated before and it is the variant that will be discussed in our study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
159

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2017

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

October 17, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 27, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2018

Completed
Last Updated

May 1, 2018

Status Verified

April 1, 2018

Enrollment Period

5 months

First QC Date

October 17, 2017

Last Update Submit

April 29, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cumulative postoperative fentanyl consumption (total dose given in micrograms)

    For 24 hours after surgery

Secondary Outcomes (8)

  • Cumulative intraoperative fentanyl consumption (total dose given in micrograms)

    For 4 hours after start of anaesthesia

  • Heart rate

    For 4 hours after start of anaesthesia

  • Mean arterial blood pressure (mmHg)

    For 4 hours after start of anaesthesia

  • Dermatomal distribution of the extent of the blockade will be assessed by pinprick method

    the first one hour after surgery

  • Postoperative pain severity will be assessed using VAS

    For 24 hours after surgery

  • +3 more secondary outcomes

Study Arms (3)

Quadratus lumborum block Group (QL)

EXPERIMENTAL

Quadratus lumborum block will be performed

Other: Quadratus lumborum block Group (QL)Drug: Paracetamol infusionDrug: Ketorolac analgesiaDrug: fentanyl

Transversus abdominis plane Group (TAP)

EXPERIMENTAL

Subcostal transversus abdominis plane will be performed

Other: Transversus abdominis plane Group (TAP)Drug: Paracetamol infusionDrug: Ketorolac analgesiaDrug: fentanyl

Control group (C)

EXPERIMENTAL

Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac

Other: Control group (C)Drug: Paracetamol infusionDrug: Ketorolac analgesiaDrug: fentanyl

Interventions

20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery

Quadratus lumborum block Group (QL)

20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery

Transversus abdominis plane Group (TAP)

No intervention will be done

Control group (C)

Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.

Control group (C)Quadratus lumborum block Group (QL)Transversus abdominis plane Group (TAP)

In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.

Control group (C)Quadratus lumborum block Group (QL)Transversus abdominis plane Group (TAP)

With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.

Control group (C)Quadratus lumborum block Group (QL)Transversus abdominis plane Group (TAP)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • American Physical Status I or II

You may not qualify if:

  • Patient refusal.
  • Hematological diseases
  • bleeding disorders.
  • Coagulation abnormality.
  • Psychiatric diseases.
  • Local skin infection
  • sepsis at site of the block.
  • Known intolerance to the study drugs.
  • Body Mass Index \> 40 Kg/m2.
  • Emergency laparoscopic cholecystectomy
  • if laparoscopic procedure converted to open.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Mansoura University, Faculty of Medicine

Al Mansurah, DK, 050, Egypt

Location

Mansoura University

Al Mansurah, DK, 050, Egypt

Location

MeSH Terms

Interventions

Control GroupsFentanyl

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethodsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Mohamed Y Makharita, MD

    Professor of Anesthesia and Surgical Intensive Care

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 17, 2017

First Posted

October 27, 2017

Study Start

October 1, 2017

Primary Completion

March 1, 2018

Study Completion

March 15, 2018

Last Updated

May 1, 2018

Record last verified: 2018-04

Locations